Results 41 to 50 of about 2,583,576 (275)

MOLECULAR MECHANISMS OF INHIBITOR DEVELOPMENT IN HEMOPHILIA

open access: yesMediterranean Journal of Hematology and Infectious Diseases, 2020
The development of neutralizing antibodies in hemophilia is a serious complication of factor replacement therapy. These antibodies, also known as “inhibitors”, significantly increase morbidity within the hemophilia population and lower the quality of ...
Davide Matino   +2 more
doaj   +1 more source

Model‐Informed Drug Development Applications and Opportunities in mRNA‐LNP Therapeutics

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The utilization of lipid nanoparticles (LNP) for encapsulating mRNA has revolutionized the field of therapeutics, enabling the rapid development of COVID‐19 vaccines and cancer vaccines. However, the clinical development of mRNA‐LNP therapeutics faces numerous challenges due to their complex mechanisms of action and limited clinical experience.
Jiawei Zhou   +6 more
wiley   +1 more source

On TRacK With Larotrectinib in a Neonate With a Giant Congenital ETV6::NTRK3 Fusion‐Positive Infantile Fibrosarcoma of the Head and Neck

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Infantile fibrosarcoma (IFS) is a rare pediatric tumor of intermediate malignancy with high local aggressiveness that typically presents in young infants. Its occurrence in the head and neck region is rare. Complete non‐mutilating surgical resection is often not possible, requiring multimodal treatment.
Teresa M. Cardesa‐Salzmann   +14 more
wiley   +1 more source

Effect of pulsed electromagnetic fields on clinical signs and quality of life in patients with hemophilic arthropathy of the knee joint: A randomized controlled trial

open access: yesAdvanced Biomedical Research, 2020
Background: Hemophilic arthropathy (HA) causes severe joint damage and impairs the quality of life (QoL) of hemophiliacs. This study was undertaken to evaluate the effect of pulsed electromagnetic fields (PEMFs) on the clinical signs and QoL of patients ...
Azam Khami   +5 more
doaj   +1 more source

Faithful flatness of Hopf algebras over coideal subalgebras with a conditional expectation [PDF]

open access: yesarXiv, 2023
Let $H$ be a Hopf algebra and let $A\subset H$ be a right coideal subalgebra. We show that if $A$ is a direct summand in $H$ as a right $A$-module, then $H$ is faithfully flat as a right $A$-module.
arxiv  

Investigating the role of SARM1 in central nervous system

open access: yesIbrain, EarlyView.
Sterile‐α and Toll/interleukin 1 receptor (TIR) motif‐containing protein 1 (SARM1) is a pivotal molecule that has garnered extensive attention in neuroscience. As an intracellular molecule, SARM1 possesses various crucial biological functions in the nervous system.
Junjie Wang   +4 more
wiley   +1 more source

New therapies for von Willebrand disease

open access: yesBlood Advances, 2019
: The management of von Willebrand disease (VWD) is based upon the dual correction of the primary hemostasis defect, due to the inherited deficiency of von Willebrand factor (VWF), and of the secondary defect of factor VIII coagulant activity (FVIII:C ...
Pier Mannuccio Mannucci
doaj  

Emicizumab in the treatment of hemophilia A [PDF]

open access: yesActa Stomatologica Naissi, 2020
Introduction: Despite substantial advances in the treatment of Hemophilia A with the use of concentrated factor VIII preparations during recent decades, bleeding episodes still occur from time to time.
Tijanić Ivan R.   +3 more
doaj  

Chinese Expert Consensus on Pharmacokinetics Guided Treatment for Hemophilia A

open access: yes罕见病研究, 2022
Hemophilia A is an X-chromosome-linked recessive genetic disease that lacks coagulation factor Ⅷ (Factor Ⅷ, FⅧ) and is clinically manifested as spontaneous or excessive bleeding after injury.The current main treatment for hemophilia A is alternative ...
Hemophilia Treatment Center Collaborative Network of China
doaj   +1 more source

Efanesoctocog Alfa Population Pharmacokinetics and Repeated Time‐To‐Event Analysis of Bleeds in Adults, Adolescents, and Children with Severe Hemophilia A

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract Efanesoctocog alfa is a first‐in‐class high‐sustained factor VIII (HSF) replacement therapy for treatment of hemophilia A. This article presents population pharmacokinetics (PopPK) of efanesoctocog alfa and repeated time‐to‐event (RTTE) analysis of bleeding episodes in adults/adolescents (≥12 years of age) and children (<12 years).
Nancy Wong   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy